BG101175A - Anti-hiv triple combination - Google Patents
Anti-hiv triple combinationInfo
- Publication number
- BG101175A BG101175A BG101175A BG10117597A BG101175A BG 101175 A BG101175 A BG 101175A BG 101175 A BG101175 A BG 101175A BG 10117597 A BG10117597 A BG 10117597A BG 101175 A BG101175 A BG 101175A
- Authority
- BG
- Bulgaria
- Prior art keywords
- hiv
- triple combination
- aids
- treatment
- loviride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94201897 | 1994-07-01 | ||
| PCT/EP1995/002462 WO1996001110A2 (en) | 1994-07-01 | 1995-06-23 | Anti-hiv triple combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG101175A true BG101175A (en) | 1997-08-29 |
Family
ID=8217000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG101175A BG101175A (en) | 1994-07-01 | 1997-01-27 | Anti-hiv triple combination |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0768881B1 (et) |
| JP (1) | JP2945481B2 (et) |
| KR (1) | KR100218495B1 (et) |
| CN (1) | CN1091599C (et) |
| AP (1) | AP9600896A0 (et) |
| AT (1) | ATE218867T1 (et) |
| AU (1) | AU693911B2 (et) |
| BG (1) | BG101175A (et) |
| BR (1) | BR9508201A (et) |
| CA (1) | CA2193489A1 (et) |
| CZ (1) | CZ375596A3 (et) |
| DE (1) | DE69527066T2 (et) |
| EE (1) | EE9600180A (et) |
| FI (1) | FI965292A0 (et) |
| HU (1) | HUT77720A (et) |
| IL (1) | IL114415A0 (et) |
| MX (1) | MX9700044A (et) |
| MY (1) | MY130597A (et) |
| NO (1) | NO965556L (et) |
| OA (1) | OA10341A (et) |
| PL (1) | PL317891A1 (et) |
| SK (1) | SK168196A3 (et) |
| TW (1) | TW401303B (et) |
| WO (1) | WO1996001110A2 (et) |
| ZA (1) | ZA955471B (et) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008539A1 (en) * | 1996-08-26 | 1998-03-05 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| JP4919566B2 (ja) | 1999-09-24 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗ウイルス組成物 |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| EP2435052B1 (en) | 2009-05-27 | 2015-07-15 | Hetero Research Foundation | Solid oral dosage forms of lamivudine with isomalt |
| WO2018119371A1 (en) * | 2016-12-23 | 2018-06-28 | Temple University - Of The Commonwealth System Of Higher Education | Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0513917T4 (da) * | 1991-05-16 | 2001-06-25 | Glaxo Group Ltd | Antivirale kombinationer indeholdende nukleosidanaloger |
-
1994
- 1994-05-25 TW TW084105260A patent/TW401303B/zh active
-
1995
- 1995-06-23 WO PCT/EP1995/002462 patent/WO1996001110A2/en active IP Right Grant
- 1995-06-23 EP EP95924930A patent/EP0768881B1/en not_active Expired - Lifetime
- 1995-06-23 EE EE9600180A patent/EE9600180A/et unknown
- 1995-06-23 BR BR9508201A patent/BR9508201A/pt not_active Application Discontinuation
- 1995-06-23 AU AU29248/95A patent/AU693911B2/en not_active Ceased
- 1995-06-23 PL PL95317891A patent/PL317891A1/xx unknown
- 1995-06-23 DE DE69527066T patent/DE69527066T2/de not_active Expired - Fee Related
- 1995-06-23 CN CN95193943A patent/CN1091599C/zh not_active Expired - Fee Related
- 1995-06-23 SK SK1681-96A patent/SK168196A3/sk unknown
- 1995-06-23 JP JP8503654A patent/JP2945481B2/ja not_active Expired - Fee Related
- 1995-06-23 CZ CZ963755A patent/CZ375596A3/cs unknown
- 1995-06-23 MX MX9700044A patent/MX9700044A/es unknown
- 1995-06-23 CA CA002193489A patent/CA2193489A1/en not_active Abandoned
- 1995-06-23 AP APAP/P/1996/000896A patent/AP9600896A0/en unknown
- 1995-06-23 AT AT95924930T patent/ATE218867T1/de not_active IP Right Cessation
- 1995-06-23 HU HU9603627A patent/HUT77720A/hu unknown
- 1995-06-30 IL IL11441595A patent/IL114415A0/xx unknown
- 1995-06-30 ZA ZA955471A patent/ZA955471B/xx unknown
- 1995-06-30 MY MYPI95001822A patent/MY130597A/en unknown
-
1996
- 1996-12-23 NO NO965556A patent/NO965556L/no unknown
- 1996-12-27 KR KR1019960707474A patent/KR100218495B1/ko not_active IP Right Cessation
- 1996-12-31 FI FI965292A patent/FI965292A0/fi not_active Application Discontinuation
- 1996-12-31 OA OA60946A patent/OA10341A/en unknown
-
1997
- 1997-01-27 BG BG101175A patent/BG101175A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA955471B (en) | 1996-12-30 |
| KR100218495B1 (en) | 1999-09-01 |
| EP0768881A2 (en) | 1997-04-23 |
| TW401303B (en) | 2000-08-11 |
| AU693911B2 (en) | 1998-07-09 |
| HUT77720A (hu) | 1998-07-28 |
| FI965292A (fi) | 1996-12-31 |
| MY130597A (en) | 2007-07-31 |
| EP0768881B1 (en) | 2002-06-12 |
| JP2945481B2 (ja) | 1999-09-06 |
| JPH09507858A (ja) | 1997-08-12 |
| SK168196A3 (en) | 1997-05-07 |
| EE9600180A (et) | 1997-06-16 |
| IL114415A0 (en) | 1995-10-31 |
| ATE218867T1 (de) | 2002-06-15 |
| AP9600896A0 (en) | 1997-01-31 |
| CN1091599C (zh) | 2002-10-02 |
| NO965556D0 (no) | 1996-12-23 |
| OA10341A (en) | 1997-10-07 |
| CN1151697A (zh) | 1997-06-11 |
| AU2924895A (en) | 1996-01-25 |
| DE69527066D1 (de) | 2002-07-18 |
| WO1996001110A3 (en) | 1996-02-22 |
| CA2193489A1 (en) | 1996-01-18 |
| WO1996001110A2 (en) | 1996-01-18 |
| MX9700044A (es) | 1997-04-30 |
| CZ375596A3 (en) | 1997-04-16 |
| PL317891A1 (en) | 1997-04-28 |
| HU9603627D0 (en) | 1997-02-28 |
| BR9508201A (pt) | 1997-11-11 |
| FI965292A0 (fi) | 1996-12-31 |
| DE69527066T2 (de) | 2003-02-13 |
| NO965556L (no) | 1996-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0831873A4 (en) | COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS | |
| WO2001010456A3 (en) | Peptides that block viral infectivity and methods of use thereof | |
| WO1993017651A3 (de) | Antivirale nucleosidanaloge, ihre herstellung und ihre verwendung | |
| AU4985496A (en) | Administration of a cyclosporine-specific monoclonal antibody that cross-reacts with hiv-1 p24 gag to treat hiv infection | |
| AU1224100A (en) | Reference clones and sequences for non-subtype b isolates of human immunodeficiency virus type 1 | |
| EP0853662A4 (en) | NEW PROVIRAL CLONE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2) WITH POSSIBILITY OF REPLICATION, CALLED HIV-2KR | |
| MY127808A (en) | Use of dideoxy nucleoside analogues in the treatment of viral infections | |
| AP9600896A0 (en) | Anti-HIV triple combination. | |
| AP2000001971A0 (en) | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine. | |
| AU5848794A (en) | Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use | |
| AU4088697A (en) | Postinfection human immunodeficiency virus (hiv) vaccination therapy | |
| HUP0000344A2 (hu) | Lamivudint és zidovudint tartalmazó gyógyszerkészítmények | |
| GB9417249D0 (en) | A novel salt | |
| AU2880595A (en) | Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses | |
| CA2285463A1 (en) | A combination therapy for hiv infections | |
| EP0323157A3 (en) | Antiviral compounds and methods | |
| AU4111600A (en) | The use of gssg reductase for the therapy and prophylaxis of hiv infected patients | |
| EP0316592A3 (en) | 3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application | |
| ZA945416B (en) | Method of inhibiting the production of infectious human immunodeficiency viruses (HIV) in HIV seropositive humans. | |
| PL317876A1 (en) | Combined treatment of hiv infections | |
| AU3593095A (en) | Method of treatment of human immunodeficiency virus (hiv) infection | |
| ZA945418B (en) | Method of inhibiting the replication of human immunodeficiency viruses (HIV) in HIV seropositive humans. | |
| AP9801368A0 (en) | Benzamide treatment of mentia associated with HIV AIDS VIRUS (HIV-1) infection | |
| AU1189899A (en) | Inhibition of human immunodeficiency virus (hiv-1) replication | |
| AU2880495A (en) | Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |